The companies will work to integrate Prevencio's protein-based blood tests into Quadrant's care pathways to better translate the results into clinical action and measure outcomes.
SYRACUSE, N.Y., Sept. 23, 2020 /PRNewswire/ -- Quadrant Biosciences Inc., a developer of epigenetic diagnostic tools, announced today that it has received an Emergency Use Authorization (EUA) from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback